Gilead Sciences (NASDAQ:GILD) Trading Down 0.5%

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) were down 0.5% during trading on Friday . The company traded as low as $66.01 and last traded at $66.27. Approximately 846,743 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 7,531,644 shares. The stock had previously closed at $66.59.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GILD shares. Morgan Stanley lowered their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Barclays lowered their target price on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. Royal Bank of Canada reissued a “sector perform” rating and set a $74.00 target price on shares of Gilead Sciences in a research note on Monday. Finally, HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price for the company in a research note on Wednesday, April 24th. Twelve investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Hold” and an average price target of $83.47.

Gilead Sciences Trading Up 0.0 %

The company has a market cap of $83.00 billion, a price-to-earnings ratio of 184.08, a P/E/G ratio of 2.83 and a beta of 0.18. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The firm has a fifty day moving average price of $66.06 and a 200 day moving average price of $72.25.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.37 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.62%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio is 855.56%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.29% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Etesian Wealth Advisors Inc. grew its holdings in shares of Gilead Sciences by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 128 shares during the last quarter. Financial Counselors Inc. lifted its stake in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 128 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 130 shares in the last quarter. Steph & Co. increased its holdings in shares of Gilead Sciences by 1.9% during the fourth quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock valued at $611,000 after acquiring an additional 142 shares in the last quarter. Finally, First Affirmative Financial Network increased its holdings in shares of Gilead Sciences by 3.5% during the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after acquiring an additional 147 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.